alexa
Reach Us +1-504-608-2390
Cyclo (His-Pro) Protects SOD1G93A Microglial Cells from Paraquatand#8211;Induced Toxicity | OMICS International
ISSN: 2155-9899
Journal of Clinical & Cellular Immunology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cyclo (His-Pro) Protects SOD1G93A Microglial Cells from Paraquat–Induced Toxicity

Silvia Grottelli1, Ilaria Bellezza1, Giulio Morozzi1, Matthew J Peirce1, Cristina Marchetti2, Ivana Cacciatore3, Egidia Costanzi1 and Alba Minelli1*
1Dipartimento Medicina Sperimentale, Piazzale Gambuli, Italy
2Dipartimento di Medicina, Università di Perugia, Piazzale Gambuli, Perugia, Itlay
3Dipartimento di Scienze del Farmaco, Università G. d’Annunzio, Italy
Corresponding Author : Alba Minelli
Dipartimento Medicina Sperimentale.Piazzale Gambuli
Edificio D. 06132. Perugia, Italy
Tel: +390755858224
E-mail: [email protected]
Received: December 16, 2014; Accepted: January 16, 2015; Published: January 23, 2015
Citation: Grottelli S, Bellezza I, Morozzi G, Peirce MJ, Marchetti C, et al. (2015) Cyclo (His-Pro) Protects SOD1G93A Microglial Cells from Paraquat–Induced Toxicity. J Clin Cell Immunol 6:287. doi:10.4172/2155-9899.1000287
Copyright: © 2015 Minelli A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Clinical & Cellular Immunology

Abstract

Cyclo (His-Pro), an endogenous cyclic dipeptide produced by the cleavage of the hypothalamic thyrotropin releasing hormone, crosses the blood brain barrier and improves recovery in models of traumatic injury to the brain and LPS-induced neuroinflammation. The protective effects are sustained by the ability of the cyclic dipeptide to interfere with the Nrf2–NF-κB signalling systems, the former governing the antioxidant and the latter the proinflammatory cellular response. Amyotrophic lateral sclerosis is a fatal disease which affects motor neurons and causes death of the patient from respiratory failure within a few years following diagnosis. Most patients suffer from sporadic amyotrophic lateral sclerosis, but about 5–10% of all amyotrophic lateral sclerosis cases can be attributed to familial forms, which are caused by mutations in the gene encoding for superoxide dismutase1. Transgenic mice overexpressing the human gene encoding for superoxide dismutase1 mutated in Gly93-Ala recapitulate several aspects of the disease. By exposing microglial cells overexpressing the mutated human gene superoxide dismutase1 to paraquat, we investigated whether cyclo (His-Pro) is able to alleviate the oxidative stress in a pathological environment. We found that cyclo (His-Pro) was effective in triggering, through Nrf2 activation, the antioxidant response which resulted primarily in the elevation of the intracellular glutathione levels. Intriguingly, we also found that cyclo (His-Pro) acts as a neurotrophic agent by inducing neuronal differentiation in PC12 cells.

Keywords
Amyotrophic lateral sclerosis; Nrf2; NF-κB; MAP kinases; BDNF
Abbreviations
Akt: protein kinase B; ALS: Amyotrophic Lateral Sclerosis; Bdnf: Brain Derived Neurotrophic Factor; CCM: Cell Conditioned Medium; ERK 1/2: Extracellular-Signal-Regulated Kinases; Gapdh: Glyceraldehyde-3-phosphate-dehydrogenase; Gclc: Glutamate cysteine ligase catalytic subunit; Gclm: Glutamate cysteine ligase modifier subunit; Gdnf: Glial cell line Derived Neurotrophic Factor; gp91phox: Heme-binding membrane glycoprotein gp91phox; GSH: Reduced Glutathione; JNK: C-Jun N-terminal Kinase; LPS: lipopolysaccaride; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; Ngf: Nerve Growth Factor; Nqo1: NAD (P)H: quinone oxidoreductase 1; Nrf2: Nuclear factor (erythroid-derived 2)-like 2; PQ: Paraquat; Prdx1: Peroxiredoxin 1; ROS: Reactive Oxygen Species; SOD1: Superoxide Dismutase 1; Tnfα: Tumor necrosis factor alpha; xCT: Cystine/glutamate Transporter.
Introduction
Amyotrophic Lateral Sclerosis (ALS) is a devastating disease affecting motor neurons in the motor cortex, brain stem, and spinal cord, leading to axon degeneration, muscle atrophy, paralysis, and death of the patient from respiratory failure within a few years following diagnosis. Most patients suffer from sporadic ALS, but about 5–10% of all ALS cases can be attributed to familial forms, which are caused by mutations in the gene encoding for Superoxide Dismutase 1 (SOD1) [1]. Transgenic mice overexpressing the human gene encoding for SOD1 mutated in Gly93-Ala (SOD1G93A) recapitulate several aspects of the disease and provide a powerful model system to identify pathophysiological mechanisms associated with ALS and to screen potential therapeutics [2,3]. The mutant SOD1 proteins can either be/become misfolded and consequently oligomerize into increasingly high-molecular-weight species that ultimately lead to the death of motor neurons (oligomerization hypothesis), or catalyze oxidative reactions that damage substrates critical for viability of the affected cells (oxidative damage hypothesis) [4]. Indeed, the pathological mechanism of the disorder likely involves protein aggregation, oxidative stress, excitotoxicity, and mitochondrial dysfunction [1]. These factors eventually lead to loss of neuromuscular junction integrity, retrograde axonal degeneration, and motoneuronal cell death. It is widely accepted that motor neuron death in ALS is not cell autonomous but depends upon active and passive roles for ambient glial cells. Glial cells in the vicinity of motor neurons contribute importantly to ALS pathophysiology [5]. Indeed, spinal astrocytosis and microgliosis accompany the onset of clinical symptoms in transgenic ALS mice [6,7]. Pro-inflammatory cytokines, chemokines, prostaglandins and oxygen radicals accumulate in tandem with reactive gliosis in spinal cords of symptomatic mice [8-10], leading to proposed secreted glial factors being pathogenic in ALS. Cyclo (His-Pro) (CHP), an endogenous cyclic dipeptide produced by the cleavage of the hypothalamic thyrotropin releasing hormone, crosses the blood brain barrier and improves recovery in models of traumatic injury to the brain and LPS-induced neuroinflammation [11-13]. Cyclo (His-Pro) protective effects are sustained by the ability of the cyclic dipeptide to interfere with the Nrf2–NF-κB signalling systems, the former governing the antioxidant and the latter the pro-inflammatory cellular response [14-16]. Cyclo (His-Pro) can exert cytoprotection against oxidative insults by activating Nrf2- leading to the up-regulation of antioxidant cellular defence [17]. Therefore, a potential therapeutic use of cyclo (His-Pro) against oxidative stress-related disease has already been proposed [12]. Paraquat (PQ) is a redox cycling agent which, by interfering with electron transfer in the mitochondria, produces destructive Reactive Oxygen Species (ROS) and oxidative stress [15,16,18].
Therefore, by exposing microglial cells overexpressing the mutated human gene SOD1G93A to a pro-oxidant agent such as paraquat, we aimed to determine whether cyclo (His-Pro) is able to alleviate the oxidative stress in a SOD1G93A environment.
Materials and Methods
Materials
Cyclo (His-Pro) was synthesized as described elsewhere [19]. All the reagents, unless otherwise stated, were from Sigma-Aldrich (St. Louis, MO). All the antibodies, unless otherwise stated, were from Santa Cruz Biotech (Santa Cruz, CA). Cell culture reagents were from Life Technologies (GibcoBRL, Gaithersburg, MD).
Immortalized microglia
Immortalized microglial cells, obtained from embryonic (E14) cortices from hSOD1G93A mice according to Righi and colleagues [20], were a kind gift of Dr. G. Pietrini (Università di Milano). Microglia were then characterized by Western blot and immunofluorescence for the presence of selective markers (colony stimulating factor 1, CSF-1) and the absence of astrocyte-specific molecules (i.e., glial fibrillary acidic protein, GFAP).
Cell cultures and viability
hSOD1G93A microglial cells were cultured in DMEM F12 supplemented with 5% Foetal Bovine Serum (FCS), glutamine (4 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml) at 37°C in a humidified 5% CO2 environment. After 24 h subculture, cells were incubated for 24 h with 50 μM cyclo (His-Pro) and then exposed to Paraquat (PQ) for various time. Inhibitors, dicumarol (NAD (P)H: quinone oxidoreductase 1) and apocynin (NADPH oxidase), were added to hSOD1G93A microglial cells, either in the presence or in the absence of 50 μM cyclo (His-Pro), 1h prior to 25 μM PQ exposure. PC12 cells were purchased from ATCC (Manassas, VA) and cultured as described by Minelli et al. [15,16]. After 24 h subculture, cells were exposed to cell conditioned medium (CCM) from hSOD1G93A microglial cells treated for 24 h with 25 μM PQ, either in the presence or in the absence of 50 μM cyclo (His-Pro). Viable cells, stained with Trypan blue, were counted using a hemocytometer. Results were expressed as the percentages of viable cells assuming the viability of control cells as 100%. Cell redox activity was measured using the 3- [4,5-dimethylthiazol-2-yl]-2,5-dephenyl tetrazolium bromide (MTT) reduction assay. The dark blue formazan crystals formed in intact cells were solubilized with lysis buffer (10% sodium dodecylsulfate, 0.01 M HCl) and the absorbance at 550 nm was measured with a microplate reader (Seac, Florence, Italy). Results were expressed as reduced MTT assuming the absorbance of control cells as 100%.
Glutathione determination
hSOD1G93A microglial cells (3×105), seeded in 6-well plates, were treated with 50 μM cyclo (His-Pro) for 24h and then exposed to PQ (25 μM) for the indicated time. The concentration of glutathione (GSH) was determined in whole cell lysate after perchloric acid precipitation using the dithionitrobenzoic acid (DTNB) method, measuring the absorbance at 412 nm (molar extinction coefficient 13.6 mmol-1cm-1) [21]. GSH levels were expressed as nmoles/mg protein.
Measurement of intracellular fluorescence
The 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) method was used to detect the levels of intracellular ROS [22]. DCFHDA diffuses into cells, where it is hydrolyzed by intracellular esterase to polar 2’,7’-dichlorodihydrofluorescein. This non-fluorescent fluorescein analogue gets trapped inside the cells and is oxidized by intracellular oxidants to a highly fluorescent, 2’,7’-dichlorofluorescein, and fluorescence intensity is proportional to the amount of oxidant species produced by the cells. hSOD1G93A microglial cells (1×104), seeded in 96-well plates, were loaded with DCFH-DA (10 μM) for 30 min at 37°C. The fluorescence of 2’,7’-dichlorofluorescein was detected at 485 nm excitation and at 535 nm emission, using a microplate reader Titertek Fluoroscan II (Flow Laboratories, McLean, VA, USA). Results, expressed as percentage of the control DCF fluorescence, were normalized to cell viability
Apoptosis determination by flow cytometry
hSOD1G93A microglial cells were incubated with 50μM cyclo (His- Pro) for 24 h and then exposed to PQ for a further 24h prior to propidium iodide (PI) (50 μg/ml in 0.1% sodium citrate plus 0.1% triton X-100) addition. The PI fluorescence of individual nuclei was measured by flow cytometry using standard FACScan equipment (Becton Dickinson, Franklin Lakes, NJ). The data were recorded in a Hewlett Packard (H9 9000, model 310, Palo Altp, CA) computer. The percentage of apoptotic cell nuclei (sub-diploid DNA peak in the DNA fluorescence histogram) was calculated with specific FACScan research software (Lysis II). At least 10,000 events were analysed in each sample.
Real time PCR
Total RNA was isolated with TRIZOL Reagent (Invitrogen Ltd, Paisley, UK) according to the manufacturer's instructions and cDNA was synthesised using iScript cDNA synthesis kit (Bio-Rad Lab, Hercules, CA.). Real time PCR was performed using the iCycler iQ detection system (Bio-Rad) and SYBR Green chemistry. Primer sequences are listed in Table 1. SYBR Green RT-PCR amplifications were carried out in a 96-well plate in a 25 μl reaction volume that contained 12.5 μl of 2x iQ™ SYBR® Green JumpStart™ Taq ReadyMix™, 400 nM forward and reverse primers, and 5 to 40 ng of cDNA. In each assay, no-template controls were included and each sample was run in triplicates. The thermal profile consisted of incubation at 95°C 3 min, followed by 40 cycles of denaturation for 10 s at 95°C and an annealing/extension step of 30 s at 62°C. Mean of Ct values of the stimulated sample was compared to the untreated control sample. ΔCt is the difference in Ct values derived from the target gene (in each assayed sample) and Gapdh, while ΔΔ Ct represents the difference between the paired samples. The n-fold differential ratio was expressed as 2-ΔΔ Ct.
Western Blotting analyses
hSOD1G93A total microglial cell lysate was obtained using boiling Laemli Sample Buffer. hSOD1G93A microglial cells nuclear extract was obtained using NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL) according to manufacturer’s instruction. Extracts were loaded on SDSpolyacrylamide gel, transferred on nitrocellulose membrane and immunoblotted with phospho-NF-κB p65 (Ser536) antibody (1:1000), phospho-Akt (Ser 473) antibody (1:1000), Akt antibody (1:1000), phospho-p38 MAPK ( Thr 180/Tyr 182) antibody (1:1000), p38 MAPK antibody (1:1000), phospho-p44/42 MAPK (ERK 1/2) (Thr 202/Tyr 204) antibody (1:1000), p44/42 MAPK (ERK 1/2) antibody (1:10000), phospho-SAPK/JNK (Thr 183/Tyr 185) antibody (1:1000), SAPK/JNK antibody (1:1000) (Cell Signalling Technology,Danvers, MA), Nrf2 (C-20) antibody (1:200), and horseradish peroxidaseconjugated -anti IgG antibody (1:5000). Lamin B (C-20) (1:200) and GAPDH (6-C5) (1:500) antibodies were used as marker proteins for nuclear/total extracts. Immunocomplexes were visualized with an enhanced chemiluminescence kit (ECL, Pierce Biotechnology, Rockford, IL).
Actin Labeling
Phalloidin was used to detect filamentous actin (F-actin) content on hSOD1G93A microglial and PC12 cells. Cells, seeded on glass coverslips, were fixed with 4% paraformaldehyde for 20 minutes at room temperature and F-actin was stained with tetramethylrhodamine (TRITC)-labeled phalloidin (1:250) for 30 minutes at room temperature. Cells were washed with PBS and cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). After mounting, the cells were viewed on a DM Rb epifluorescence microscope (Leica, Wetzlar, Germany) equipped with a digital camera.
Statistical analysis
All results, confirmed in at least 3 separate experiments, were subjected to one-way or two-way Analyses of Variance (ANOVA). Post-hoc comparisons were performed using Dunnett’s tests (p<0.05).
Results
Cyclo (His-Pro) alleviates paraquat toxic effects in hSOD1G93A microglial cells.
To determine whether the cyclic dipeptide (His-Pro) is capable of counteracting the deleterious effects of PQ, we first evaluated PQ toxicity in hSOD1G93A microglial cells (Figure 1A).
We found that decreases in cell redox activity were concentrationdependent up to a 24h exposure, whereas, a 48h exposure resulted in a marked decrease in cell redox activity even at very low PQ concentration. In our study we used 25 μM PQ, since a 24h exposure caused the loss of 40% cell redox activity. A 24h pre-treatment with 50 μM cyclo (His-Pro), confirmed as the minimum effective concentration [23], significantly protected the hSOD1G93A microglial cells from PQ-induced toxicity by rescuing cell redox activity (Figure 1B).
While PQ exposure did not decrease cell viability, cyclo (His-Pro) significantly increased cell viability vs. PQ (Figure 1C). Phalloidinstained images showed a striking change of microglia shape following a 24h PQ-exposure (Figure 1D) but cellular morphology nearly reverted to control in mutant microglial cells pre-treated with cyclo (His-Pro), indicating an attenuation of PQ toxicity. PQ did not cause increases in apoptosis (Figure 1E) nor NO production (data not shown). We also observed that cyclo (His-Pro) caused an early and sustained increase in GSH cellular levels (Figure 2A) and significantly decreased PQ-induced ROS generation (Figure 2B).
Cyclo (His-Pro) acts via MAP kinases in hSOD1G93A microglial cells.
We have previously shown that the effects of cyclo (His-Pro) are mediated by the concomitant activation and/or disactivation of various MAPK pathways [23]. To investigate the mechanism of cyclo (His-Pro) at the signalling level, we examined the activation of extracellular-signal-regulated kinases (ERK 1/2), p38 kinase, C-Jun Nterminal Kinase (JNK), and protein kinase B (Akt), known to be involved in the responses to various stressors and in cell survival (Figure 3).
Cyclo (His-Pro) inhibited PQ-induced ERK 1/2 phosphorylation at 15 min without affecting phospho-p38 levels, also unmodified by PQ. On the other hand, the cyclic dipeptide delayed the PQ-induced AKT inactivation and slightly decreased the JNK phosphorylation at 60 min.
Cyclo (His-Pro) activates Nrf2-antioxidant response in hSOD1G93A microglial cells.
We have already provided evidence consistent with the notion that cyclo (His-Pro) exerts cytoprotection by interfering with the Nrf2–NF- κB systems, the former controlling the antioxidant and the latter the pro-inflammatory cellular response [12,14-16]. To verify whether cyclo (His-Pro) uses the same mechanism to relieve the PQ-induced cytotoxic effects in the hSOD1-mutated microglial cells, we analysed the activation of Nrf2 and NF-κB. We found that cyclo (His-Pro) induces a remarkable nuclear translocation of Nrf2 that lasts up to 3h, while not modifying the slight PQ-induced activation of NF-κB (Figure 4A and 4B). Nuclear translocation can be regarded as a marker of activation [24,25].
Indeed, we found that cyclo (His-Pro) induced a robust upregulation of the mRNA levels of Nrf2-driven genes, such as Gclc, Gclm, xCT, and Nqo1, while no effect was observed on the transcription of the NF-κB–driven genes, such as Tnfα, Prdx1, and gp91phox (Figure 4C and 4D). It is noteworthy that the up-regulation of glutathione synthesising enzymes and cystine-glutamate transporter are in accordance with the increased GSH levels found in cyclo (His- Pro)-treated hSOD1G93A microglia cells.
To establish a causal link between the up-regulation of genes such as Nqo1 by cyclo (His-Pro) and decreased ROS production, we treated hSOD1G93A microglial cells with dicumarol, a NQO1 inhibitor, and with apocynin, an inhibitor of NADPH oxidase activity which generates ROS independent of NQO1. We then determined the level of ROS generation in the presence of PQ and cyclo (His-Pro) (Figure 4E). The inhibition of NQO1 abrogated the cyclo (His-Pro)-induced decreases in ROS production whereas the inhibition of NADPH oxidase did not counteract the cyclo (His-Pro) effects in decreasing ROS generation.
Cyclo (His-Pro) induces brain-derived neurotrophic factor expression in hSOD1G93A microglial cells.
Microglial cells modulate the pathological and /or regenerative state of the brain by producing a variety of physiologically-active substances, such as neurotrophic molecules [26]. To further investigate the beneficial effects of cyclo (His-Pro) on the PQ-stressed hSOD1G93A microglial cells, we determined the transcriptional effects of the cyclic dipeptide on the expression of various neurotrophins (Figure 5A). Although PQ treatment did not alter Bdnf gene expression, the cyclic dipeptide caused a robust up-regulation of the mRNA levels either alone or in combination with PQ. As a functional read-out of the Bdnf up-regulation, we used neuroblastic PC12 cells as a model of neurite outgrowth induced by neurotrophic factors [27,28].
We analysed PC12 neuronal differentiation in the presence of conditioned media obtained by cyclo (His-Pro)-treated hSOD1G93A microglial cells (Figure 5B). Conditioned media obtained from hSOD1G93A microglial cells treated with cyclo (His-Pro) alone caused a drive towards neuronal differentiation in PC12 cells. In addition, conditioned media from hSOD1G93A microglial cells treated with cyclo (His-Pro) before PQ exposure were still able to drive, although at a minor extent, PC12 towards neuronal differentiation.
Discussion
Two major observations are reported in this study. First we showed that, even in the presence of the hSOD1 mutation, cyclo (His-Pro) is still able to act as an antioxidant agent. Second, the striking increase in Bdnf expression induced by cyclo (His-Pro) might lead to the proposal of cyclo (His-Pro) as a neurotrophic agent. A very complex combination of environmental and genetic factors underlies the pathophysiological origins of neurodegenerative disorders. However, in many of these disorders, processes such as inflammation and oxidative stress activate common final pathways leading to toxicity and cellular death. High levels of oxidative damage within the brain and the activation of neuroinflammatory factors are a prominent feature in patients with Amyotrophic Lateral Sclerosis (ALS) [29,30]. Although the brain, isolated from the systemic circulation by the protective blood-brain barrier has been long considered an immune privileged organ [31], the relationship between neuroinflammation and neurodegeneration is now well accepted [32-34]. Moreover, the importance of glial cells in the progression of neurodegeneration has also been recognised, since they migrate to the damaged cells where they clear the dead cell debris. However, in the process, microglia release Reactive Oxygen Species (ROS), pro-inflammatory cytokines, complement factors, and neurotoxic molecules, exacerbating inflammation and leading to further neuronal dysfunction and death [35-42]. Many data from autoptic spinal cord and blood examinations of ALS patients, as well as animal and cellular models, support a role for the immune system in ALS pathogenesis [43]. Paraquat, a widely used herbicide, has strong neurotoxic effects and is one of the major environmental risk factors for Parkinson’s disease occurrence [44]. As a redox cycling agent, PQ, by interfering with the electron transfer, produces destructive ROS and oxidative stress with associated toxicity [45-48]. Cyclo (His-Pro), originally discovered in the brain, is an endogenous cyclic dipeptide structurally related to the hypothalamic thyrotropin-releasing hormone [17]. The most intriguing function of this cyclic dipeptide is related to its neuroprotective role, first reported in traumatic injuries of the spinal cord [11], and then confirmed in an in vivo model of LPS-induced reactive gliosis [12]. Nuclear factor-like 2 (Nrf2) is a transcription factor that regulates the constitutive and inducible expression of antioxidant and phase 2 detoxification enzymes via a cis-acting DNA element called electrophile responsive element / antioxidant responsive element (EpRE/ARE) [49]. The Nrf2–ARE pathway represents a physiological adaptation to oxidative stress and its activation is the major mechanism in terminating the NF-κB-driven immune response [13,24,25]. Here we found that the treatment of hSOD1G93A microglial cells with cyclo (His-Pro) markedly reduced PQ–induced ROS production. However, it is worth noting that the production of ROS by hSOD1G93A microglial cells appeared to be a slow process and, at early time points such as a 6h PQ-exposure, only slight increases in ROS levels were observed. We initially assumed that the slow ROS generation could be explained by the fact that the SOD1 enzyme normally functions as a free radical scavenger and many SOD1 ALS mutants have superoxide-scavenging activity comparable with that of wild type SOD1 [50,51]. Moreover, we speculated that the PQ concentration used in the study, although incapable of causing apoptosis, was enough to trigger the antioxidant response by activating the Nrf2 signalling. This process resulted in significantly increased cellular GSH levels at each time-point thus leading to a robust cellular ROS detoxification. In addition, the observed up-regulation of the Nqo1 gene and the fact that cyclo (His- Pro) acts mainly via augmented NQO1 activity to reduce the ROS load might also contribute to the slow increase in ROS production. Data from the literature show that ERK 1/2, JNK and AKT are central to PQ-toxic effects while p-38 is minimally involved in cytotoxicity [46,52-55]. Consistent with these data, we found that, at the signalling level, the protective effects of cyclo (His-Pro) were achieved by inhibiting ERK 1/2 activation and delaying the inactivation of the AKT pathway. On the other hand, the PQ-mediated JNK activation was only marginally altered by the cyclic dipeptide. The discrepancy of our findings with data from other groups might reside in the fact that we used a PQ–concentration which did not cause apoptosis since the robust activation of JNK, which follows exposure to higher concentrations of PQ, drives caspase-3 activation and apoptosis. Thus, the mutated glial cells used in the study might be responsible for the lack of apoptosis even in the presence of marked early and transient JNK activation. Finally, we showed that cyclo (His-Pro) markedly upregulated Bdnf expression in hSOD1G93A microglial cells and, in the presence of PQ, the cyclic dipeptide could robustly up-regulate Bdnf gene expression. The fact that cyclo (His-Pro) alone can induce such a strong up-regulation of the Bdnf gene by hSOD1G93A microglia cells might underpin a potentially beneficial use of the cyclic dipeptide in the course of the ALS disease.
In conclusion, we showed: i) an exogenous oxidative stress on hSOD1G93A microglial cells can worsen the known deleterious effects of the mutated microglia cells; ii) the use of cyclo (His-Pro), by diminishing the oxidative burden and triggering the defence response, can, at least partially, attenuate PQ toxicity.
Acknowledgement
The Authors thank Dr Grazia Pietrini for the kind gift of hSOD1G93A microglial cells. The work was funded by Fondazione Cassa di Risparmio di Perugia (2013.0077.021).
References























































Tables and Figures at a glance

Table icon
Table 1

 

Figures at a glance

Figure Figure Figure Figure Figure
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11883
  • [From(publication date):
    February-2015 - Nov 15, 2018]
  • Breakdown by view type
  • HTML page views : 8099
  • PDF downloads : 3784
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version